Resultado de búsqueda
Ian Mongrain's 38 research works with 497 citations and 3,101 reads, including: Pharmacogenomic markers of metoprolol and α-OH-metoprolol concentrations: a genome-wide association study
View Yann (Ian) Mongrain’s profile on LinkedIn, a professional community of 1 billion members. 25+ years in the motion picture industry, specializing in new and innovative technologies. · Experience: Freelance · Location: Brossard · 270 connections on LinkedIn.
11 de ene. de 2015 · The dal-OUTCOMES Trial. The dal-OUTCOMES study was a phase 3 clinical trial testing the efficacy of the investigational cholesteryl ester transfer protein inhibitor dalcetrapib (F. Hoffmann-La Roche), as previously described. 4 Patients who were clinically stable 4 to 12 weeks after a recent acute coronary syndrome were randomized in a 1:1 ratio to dalcetrapib 600 mg daily or placebo on top of ...
Ian Mongrain has been with the Beaulieu-Saucier Pharmacogenomics Centre since its creation in 2008. His academic training in the Pharmacogenomics program at the Université de Montréal, as well as the many projects carried out with major institutions and companies such as biopharmaceuticals, ...
British Woven, Natural Fabrics. Our collection of Ian Mankin natural fabrics in a range of classic striped, checked, patterned and plain designs are available in a subtle yet contemporary colour palette that has the ability to endure changing trends. All our fabrics are beautifully designed and woven using natural cotton, linen and wool at our ...
The effects of dalcetrapib on atherosclerotic outcomes are determined by correlated polymorphisms in the ADCY9 gene. Background—Dalcetrapib did not improve clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%. These results differ from other evidence supporting high-density lipoprotein as a therapeutic target. Responses to dalcetrapib may vary according to ...
Ian Mongrain, M.Sc. Directeur des opérations. Centre pharmacogénomique Beaulieu-Saucier Institut de Cardiologie de Montréal, bureau S-2050 5000, rue Bélanger Est, Montréal Qc, Canada, H1T1C8. Bureau : 514-670-7670, 7716 CA/USA : 1-855-670-7670, 7716 Télécopieur : 1-514-670-7671. ian.mongrain@pharmacogenomics.ca
